Siming Li

14.9k total citations · 3 hit papers
122 papers, 6.1k citations indexed

About

Siming Li is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Siming Li has authored 122 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 27 papers in Oncology and 16 papers in Physiology. Recurrent topics in Siming Li's work include Melanoma and MAPK Pathways (14 papers), Adipose Tissue and Metabolism (14 papers) and Fibroblast Growth Factor Research (13 papers). Siming Li is often cited by papers focused on Melanoma and MAPK Pathways (14 papers), Adipose Tissue and Metabolism (14 papers) and Fibroblast Growth Factor Research (13 papers). Siming Li collaborates with scholars based in China, United States and Ethiopia. Siming Li's co-authors include Jiandie D. Lin, Kun‐Liang Guan, Arul M. Chinnaiyan, Bin Zhao, Jianjun Yu, Xin Ye, Cun-Yu Wang, Weiquan Li, Li Li and Jindan Yu and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Siming Li

117 papers receiving 6.0k citations

Hit Papers

TEAD mediates YAP-dependent gene induction and growth con... 2007 2026 2013 2019 2008 2007 2014 500 1000 1.5k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Siming Li China 35 3.3k 2.0k 1.3k 781 741 122 6.1k
Andrea Graziani Italy 34 3.9k 1.2× 1.0k 0.5× 1.3k 1.0× 509 0.7× 999 1.3× 97 7.3k
John W.M. Creemers Belgium 42 2.3k 0.7× 1.5k 0.8× 889 0.7× 380 0.5× 612 0.8× 116 5.6k
Diane C. Fingar United States 33 6.2k 1.9× 949 0.5× 1.2k 0.9× 941 1.2× 932 1.3× 49 8.7k
Jonathan M. Graff United States 44 4.6k 1.4× 990 0.5× 1.8k 1.4× 1.2k 1.6× 564 0.8× 63 7.4k
Simon S. Wing Canada 38 3.4k 1.1× 1.1k 0.6× 815 0.7× 632 0.8× 616 0.8× 71 4.8k
Robert A. Saxton United States 11 5.5k 1.7× 1.3k 0.7× 1.2k 0.9× 1.4k 1.8× 662 0.9× 15 8.4k
Juro Sakai Japan 50 5.2k 1.6× 1.1k 0.6× 1.6k 1.3× 955 1.2× 778 1.0× 107 8.5k
Kenta Hara Japan 39 7.5k 2.3× 1.5k 0.8× 963 0.8× 825 1.1× 648 0.9× 67 9.5k
Zengqiang Yuan China 51 5.5k 1.7× 1.7k 0.8× 952 0.8× 651 0.8× 763 1.0× 140 8.6k
Alejo Efeyan Spain 24 6.0k 1.8× 1.3k 0.7× 1.9k 1.5× 1.7k 2.2× 1.4k 1.9× 49 9.5k

Countries citing papers authored by Siming Li

Since Specialization
Citations

This map shows the geographic impact of Siming Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siming Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siming Li more than expected).

Fields of papers citing papers by Siming Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siming Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siming Li. The network helps show where Siming Li may publish in the future.

Co-authorship network of co-authors of Siming Li

This figure shows the co-authorship network connecting the top 25 collaborators of Siming Li. A scholar is included among the top collaborators of Siming Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siming Li. Siming Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Siming, J. B. Wei, Huayan Xu, et al.. (2025). A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy. World Journal of Urology. 43(1). 206–206.
3.
Zhang, Jiaran, Lili Mao, Caili Li, et al.. (2025). Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. Cancer Management and Research. Volume 17. 905–916. 1 indexed citations
4.
Zheng, Yi, et al.. (2024). Analysis of risk factors for post-thrombotic syndrome after thrombolysis therapy for acute deep venous thrombosis of lower extremities. International Journal of Cardiology Cardiovascular Risk and Prevention. 22. 200319–200319. 1 indexed citations
5.
Sun, Hong‐Mei, Q. N. Xu, Siming Li, et al.. (2024). Therapeutic Potential of Bee and Wasp Venom in Anti-Arthritic Treatment: A Review. Toxins. 16(11). 452–452. 2 indexed citations
6.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.. Journal of Clinical Oncology. 42(16_suppl). e21527–e21527. 1 indexed citations
7.
Tang, Bixia, Rong Duan, Xieqiao Yan, et al.. (2024). Natural history of bone-only metastasis in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e17–119.e22. 1 indexed citations
8.
Li, Siming, Yanxia Shi, Haiying Dong, et al.. (2024). Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Cancer Medicine. 13(21). e70368–e70368. 4 indexed citations
9.
Cui, Chuanliang, Xuan Wang, Bin Lian, et al.. (2022). OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer. 10(4). e004307–e004307. 38 indexed citations
11.
Meng, Qingqi, et al.. (2018). Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury. PPAR Research. 2018. 1–11. 10 indexed citations
12.
Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127. 72 indexed citations
13.
Guo, Liang, Peng Zhang, Zhimin Chen, et al.. (2017). Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. Journal of Clinical Investigation. 127(12). 4449–4461. 141 indexed citations
14.
Mi, Lin, Xu-Yun Zhao, Siming Li, Gongshe Yang, & Jiandie D. Lin. (2016). Conserved function of the long noncoding RNA Blnc1 in brown adipocyte differentiation. Molecular Metabolism. 6(1). 101–110. 65 indexed citations
15.
Cheng, Yunyun, Dan Su, Chao Lu, et al.. (2016). Distribution and linkage disequilibrium analysis of polymorphisms of GH1 gene in different populations of pigs associated with body size. Journal of Genetics. 95(1). 79–87. 5 indexed citations
16.
Dai, Jie, Yan Kong, Lu Si, et al.. (2013). Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. Clinical Cancer Research. 19(24). 6935–6942. 38 indexed citations
17.
Shi, Shuangxin, Dong Liang, Ling-Ling Li, et al.. (2013). [Polybrominated diphenyl ethers and polychlorinated biphenyls in road dust from Suzhou, Wuxi and Nantong].. PubMed. 34(10). 4024–30. 3 indexed citations
18.
Molusky, Matthew M., Siming Li, Di Ma, Lei Yu, & Jiandie D. Lin. (2012). Ubiquitin-Specific Protease 2 Regulates Hepatic Gluconeogenesis and Diurnal Glucose Metabolism Through 11β-Hydroxysteroid Dehydrogenase 1. Diabetes. 61(5). 1025–1035. 50 indexed citations
19.
Chi, Zhihong, et al.. (2011). A Clinical Characters and Prognosis Analysis on 357 Cases with Cutaneous Malignant Melanoma in China. Zhongliu fangzhi yanjiu. 38(11). 1316–1319. 2 indexed citations
20.
Li, Siming. (2008). The experimental study on the repair of articular cartilage defects of the knee in rabbits with type II collagen. Zhonghua chuangshang guke zazhi. 10(9). 844–849. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026